MarketPeel
Insider Trading Intelligence
TM

Tiago Marques

KTTA
CHIEF EXECUTIVE OFFICER · PASITHEA THERAPEUTICS CORP. · CIK 0001875240
FILING MIX · LIFETIME95%/5%
BUYS
19
SELLS
1
TOTAL VALUE
$45.4K
COMPANIES
1
ACTIVE SINCE
Dec 2021
HOLDINGS NOW
1,756,069
AVG SELL PX
$0.83
TRADE KIND
SHOWING 20 / 20
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 1 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Tiago Marques, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+0.00%+8.28%+2.03%+6.24%+6.24%
14d1+0.00%+4.60%+1.40%+3.20%+3.20%
30d1+100.00%-2.41%+3.15%-5.57%-5.57%
60d1+100.00%-20.80%+6.97%-27.77%-27.77%
90d1+100.00%-21.95%+9.08%-31.03%-31.03%
180d1+100.00%-20.69%+15.09%-35.78%-35.78%
1y1+100.00%-10.35%+26.62%-36.96%-36.96%
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
KTTA · 1,756,069 shares · as of May 1, 2026
0439,017878,0351,317,0521,756,06920222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 19 buys / 1 sellsCOVERAGE · 19 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
KTTA
PASITHEA THERAPEUTICS CORP.
PURCHASEGRANT
Stock grant
1,756,0691,756,069May 1, 2026May 5, 2026View →
KTTA
PASITHEA THERAPEUTICS CORP.
PURCHASE
Chief Executive Officer
33,333$0.75$25.0K73,334Nov 28, 2025Dec 1, 2025View →
KTTA
PASITHEA THERAPEUTICS CORP.
PURCHASEGRANT
Stock grant
493,341493,341Oct 24, 2025Oct 27, 2025View →
KTTA
PASITHEA THERAPEUTICS CORP.
SALE
Chief Executive Officer
960$0.83$79240,001May 12, 2025May 14, 2025View →
KTTA
PASITHEA THERAPEUTICS CORP.
PURCHASEGRANT
Stock grant
15,00015,000Mar 1, 2024Apr 5, 2024View →
KTTA
PASITHEA THERAPEUTICS CORP.
PURCHASEGRANT
Stock grant
11,66911,669Mar 1, 2024Apr 5, 2024View →
KTTA
PASITHEA THERAPEUTICS CORP.
PURCHASEGRANT
Stock grant
11,66911,669Mar 1, 2024Mar 1, 2024View →
KTTA
PASITHEA THERAPEUTICS CORP.
PURCHASEGRANT
Stock grant
15,00015,000Mar 1, 2024Mar 1, 2024View →
KTTA
PASITHEA THERAPEUTICS CORP.
PURCHASEGRANT
Stock grant
2,000$1.03$2.1K819,206Nov 25, 2022Nov 28, 2022View →
KTTA
PASITHEA THERAPEUTICS CORP.
PURCHASEGRANT
Stock grant
1,000$1.03$1.0K816,000Nov 23, 2022Nov 28, 2022View →
KTTA
PASITHEA THERAPEUTICS CORP.
PURCHASEGRANT
Stock grant
1,206$1.02$1.2K817,206Nov 23, 2022Nov 28, 2022View →
KTTA
PASITHEA THERAPEUTICS CORP.
PURCHASEGRANT
Stock grant
5,000$1.00$5.0K815,000Nov 23, 2022Nov 28, 2022View →
KTTA
PASITHEA THERAPEUTICS CORP.
PURCHASEGRANT
Stock grant
600$1.08$648805,600Oct 21, 2022Oct 21, 2022View →
KTTA
PASITHEA THERAPEUTICS CORP.
PURCHASEGRANT
Stock grant
4,400$1.07$4.7K810,000Oct 21, 2022Oct 21, 2022View →
KTTA
PASITHEA THERAPEUTICS CORP.
PURCHASEGRANT
Stock grant
1,800$0.99$1.8K805,000Jun 23, 2022Jun 23, 2022View →
KTTA
PASITHEA THERAPEUTICS CORP.
PURCHASEGRANT
Stock grant
2,900$0.99$2.9K802,900Jun 23, 2022Jun 23, 2022View →
KTTA
PASITHEA THERAPEUTICS CORP.
PURCHASEGRANT
Stock grant
200$0.98$196803,100Jun 23, 2022Jun 23, 2022View →
KTTA
PASITHEA THERAPEUTICS CORP.
PURCHASEGRANT
Stock grant
100$0.99$99803,200Jun 23, 2022Jun 23, 2022View →
KTTA
PASITHEA THERAPEUTICS CORP.
PURCHASEGRANT
Stock grant
200,000800,000Dec 20, 2021Dec 22, 2021View →
KTTA
PASITHEA THERAPEUTICS CORP.
PURCHASEGRANT
Stock grant
200,000200,000Dec 20, 2021Dec 22, 2021View →
Other insiders · KTTA
Loading peer insiders…
About this filer
CIK 0001875240
ROLE
Chief Executive Officer
PRIMARY
KTTA
COMPANIES
1
ACTIVE SINCE
Dec 2021
MARKETPEEL · /INSIDER/0001875240DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback